secwatch.observer — SEC 8-K summary
======================================

Issuer:     Z Squared Inc. (ZSQR)
CIK:        0001759186
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001683168-24-001672
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Coeptis Therapeutics restates 2022 annual and 2023 quarterly financials; prior reports no longer reliable
--------------------------------------------------------------------------------

- Audit committee determined 2022 audited and 2023 quarterly financials are unreliable due to accounting errors.
- Unrecorded liability from October 2022 merger must be booked; remaining balance immaterial and payable in 2024.
- Reimbursement commitment under a January 2023 research agreement requires restatement for Q1-Q3 2023.
- Company will file restated financial statements as soon as practicable.
- Previously disclosed material weaknesses in internal controls; new CFO hired to improve processes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759186/000168316824001672/0001683168-24-001672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759186/000168316824001672/coeptis_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-001672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer